The Efficacy and Safety of Nucleos(t)Ide Analogues in the Treatment of HBV-related Acute-on-chronic Liver Failure
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
HBV-related acute-on-chronic liver failure (ACLF) is a clinical syndrome defined as acute
hepatic insult with diagnosed or undiagnosed chronic liver disease. Current clinical
guidelines advocate oral antiviral treatment in HBV-related ACLF. However, no conclusion on
which nucleoside analogue is the most satisfactory drug for the treatment of HBV-related
liver failure has not been reached yet. In this cohort study, the investigators will compare
the efficacy, safety, and tolerability of tenofovir alafenamide (TAF), Tenofovir Disoproxil
Fumarate (TDF) and entecavir (ETV) in HBV-related ACLF in China.
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University